U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Go back to U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations| Consolidated Gems, Inc. (NASDAQ: CGEM) | Delayed: 17.30 +2.27 (15.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.03 | 52 Week High | $0.19 | |||
| Open | $15.27 | 52 Week Low | $0.03 | |||
| Day High | $17.40 | P/E | N/A | |||
| Day Low | $15.26 | EPS | $0.00 | |||
| Volume | 1,496,004 | |||||
